Pure Global
NCT06349837

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Safety and Tolerability of Low Dose Radiotherapy Plus Concurrent Partial Stereotactic Ablative Radiotherapy (Eclipse-RT) and Tislelizumab in Patients With Bulky Tumors
Sichuan University·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
Tislelizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sichuan University
Timeline & enrollment
Phase
Phase 1
Start date
Apr 15, 2024
End date
Mar 31, 2026
Enrollment
9 participants
Primary outcome

Dose Limiting Toxicities

Summary

This is a 3+3 dose escalation phase I study which aims to evaluate the safety and
 tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative
 Radiotherapy (SBRT) and Tislelizumab in Patients with bulky tumors who have failed standard
 therapy. At least 9 participants will be enrolled in this study.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06349837
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06349837 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sichuan University and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 9 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.